← Back to all trials
Recruiting
NCT07358078
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
Conditions: Transthyretin Amyloidosis With Cardiomyopathy
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 2000
Sponsor: Alnylam Pharmaceuticals
Location: Clinical Trial Site Tucson Arizona
Summary
The purpose of this study is to:
* Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care
* Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care
* Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care
* Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care
* Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care
Eligibility Criteria
Inclusion Criteria:
* Has a diagnosis of ATTR-CM
* Is initiating treatment with vutrisiran or another approved ATTR-CM therapy
Exclusion Criteria:
* Is enrolled in an interventional clinical trial
Source: ClinicalTrials.gov (NCT07358078). StuddyBuddy aggregates publicly available trial information.